Chimeric extrache is new ideas for tumor immunotherapy
Science and Technology Daily Beijing October 21 (Reporter Lu Chengwei) On the 21st, the reporter learned from the Process Project of the Chinese Academy of Sciences 上海喝茶微信 that the researchers have created a chimeric extract, achieving the dual targeting of lymph nodes and tumor tissues. The immune response in the lymph node is activated and the tumor immunization is improved.
The dual-efficiency synergistic mechanism significantly inhibits tumor progress on a variety of animal models, bringing new ideas for tumor immunotherapy. Relevant results were published online in "Science and Transformation Medicine". Substrates are cytoplasmic natural biological particles, with unique transport paths and biological functions in the body, and new dosage forms created, is expected to achieve precision delivery and expected 上海一楼一凤论坛 efficacy in a complex environment in vivo, in tumor individuals Wide application prospects in the field of treatment. "The existing most tumor immunotherapy focuses on enhancing the immunocyte function and quantity in vivo, but it is often difficult to overcome the immunosuppressive microenvironment of the solid tumor site, so that the immune cells in the tumor are difficult to effectively exert its anti-tumor function.
"The research staff of the Chinese Academy of Sciences Project Engineering said.
To this end, the researchers combined more than ten years of research experience in granule dosage form, vaccine delivery and tumor immunity, proposed lymph nodes – tumor dual-targeted outer body for dual effectiveness of tumor immunotherapy. The research team chose macrophages with strong swallowing ability to 上海水磨419论坛 intake tumor cell nucleus, form immunotent macrophages after immunization of immunostain, forming immunostatist-activated macrophages.
The cell secreted macrophages – tumor chimeric external body can inherit the function of two source cells, and double targeted to lymph nodes and tumor tissues, while achieving lymph nodes immune response activation and tumor immunochemical improvement. Wei Wei, the researcher of the Chinese Academy of Sciences Process Engineering, said that this result is a pre-clinical study, and the actual clinical efficacy remains to be further verified. Given that the materials preparing the chimeric extracted are patient self-cells, the preparation has a better transformation prospect in the field of clinical tumor individualization.